GSK’s Jemperli Receives FDA Approval for First-Line Treatment of Advanced Endometrial Cancer
GSK plc (NYSE: GSK), a major UK pharmaceutical company, has announced that the US Food...
PD-1/L1
Akeso Biopharma Reports First Positive Earnings in H1 2023 Financial Results
Akeso Biopharma (HKG: 9926) has released its financial report for the first half of 2023,...
Akeso Biopharma Initiates Phase Ia/Ib Study for TIGIT mAb AK127 in Solid Tumors Combination Therapy
China-based Akeso Biopharma (HKG: 9926) has announced the first patient enrollment in a Phase Ia/Ib...
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
BeiGene’s Tislelizumab Receives Positive CHMP Opinion for Esophageal Cancer Treatment
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received a...
HutchMed’s Elunate-Tyvyt Combo Receives Breakthrough Therapy Designation in China for Endometrial Cancer
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the combination of Elunate (fruquintinib)...
Shanghai Junshi Biosciences’ Tuoyi Receives NMPA Review for ES-SCLC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the National Medical...
Antengene Initiates Phase I ERASER Study for ATG-017 in Combination with Nivolumab
China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced the first patient dosing in...
Bio-Thera Solutions Receives NMPA Approval for CTLA-4 and PD-1 Inhibitor Combo Study
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that it has received approval from China’s...
Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...
Shanghai Junshi Biosciences’ Tuoyi Files for 9th Indication in China for RCC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...
Genprex Inc. Receives Chinese Patent Protection for Reqorsa Immunogene Therapy
Texas-based gene therapy company Genprex Inc., (NASDAQ: GNPX), has reported receiving a patent protection award...
Shanghai Junshi Biosciences Gets FDA Approval for Phase III Study of Tifcemalimab in Small-Cell Lung Cancer
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877) has announced receiving approval from the US Food...
Innovent Biologics and RemeGen Partner on Clinical Study for PD-1 Inhibitor and ADC Drugs
China-based Innovent Biologics Inc., (HKG: 1801) has entered into a clinical study and supply cooperation...
Jiangsu Hengrui’s Camrelizumab Earns Full Approval for Advanced Hepatocellular Carcinoma in China
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the transition of its programmed death-1 (PD-1)...
Bio-Thera Solutions’ PD-1 Inhibitor BAT1308 Approved for Cervical Cancer Clinical Trials in China
Bio-Thera Solutions Ltd (SHA: 688177) has announced that its programmed death-1 (PD-1) inhibitor, BAT1308, has...
Fosun Pharma Initiates Phase II Study of HLX26 and Serplulimab Combo for Metastatic CRC
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...
CStone’s Sugemalimab Shows Promising Survival Rates in Stage IV NSCLC Treatment
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the prestigious journal Nature Cancer has published...
Genor Biopharma’s Geptanolimab NDA for PTCL Rejected by China’s NMPA
China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced that the National Medical Products Administration...
Coherus and Junshi Biosciences Await FDA Decision on Toripalimab After Inspection
US-based Coherus Biosciences Inc., (NASDAQ: CHRS) has disclosed that the US FDA has recently completed...